$XBIT
XBiotech Inc

2016 Q3 Form 10-Q Financial Statement

#000117184316013213 Filed on November 14, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2015 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.690M $1.080M
YoY Change 149.07% -59.09%
% of Gross Profit
Research & Development $9.774M $9.731M
YoY Change 0.44% 124.16%
% of Gross Profit
Depreciation & Amortization $180.0K $170.0K
YoY Change 5.88% 21.43%
% of Gross Profit
Operating Expenses $12.46M $10.81M
YoY Change 15.21% 54.93%
Operating Profit -$12.46M $10.81M
YoY Change -215.21% -254.93%
Interest Expense -$30.00K $80.00K
YoY Change -137.5% 300.0%
% of Operating Profit 0.74%
Other Income/Expense, Net -$25.00K $78.00K
YoY Change -132.05% 358.82%
Pretax Income -$12.48M -$10.74M
YoY Change 16.2% 54.31%
Income Tax
% Of Pretax Income
Net Earnings -$12.48M -$10.74M
YoY Change 16.28% 54.19%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$384.7K -$335.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.80M $105.7M
YoY Change -55.72% 581.94%
Cash & Equivalents $46.79M $105.7M
Short-Term Investments
Other Short-Term Assets $2.000M $1.900M
YoY Change 5.26% 375.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $48.84M $107.6M
YoY Change -54.6% 576.65%
LONG-TERM ASSETS
Property, Plant & Equipment $10.08M $4.854M
YoY Change 107.7% 27.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $29.45M $11.46M
YoY Change 156.99% 201.58%
TOTAL ASSETS
Total Short-Term Assets $48.84M $107.6M
Total Long-Term Assets $29.45M $11.46M
Total Assets $78.29M $119.0M
YoY Change -34.23% 504.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.465M $3.964M
YoY Change 12.64% 230.33%
Accrued Expenses $2.176M $994.0K
YoY Change 118.91% -17.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.641M $4.958M
YoY Change 33.95% 106.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.641M $4.958M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $6.663M $4.970M
YoY Change 34.06% 107.08%
SHAREHOLDERS EQUITY
Retained Earnings -$167.0M -$118.8M
YoY Change 40.63%
Common Stock $238.8M $232.9M
YoY Change 2.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $71.63M $114.1M
YoY Change
Total Liabilities & Shareholders Equity $78.29M $119.0M
YoY Change -34.23% 504.3%

Cashflow Statement

Concept 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$12.48M -$10.74M
YoY Change 16.28% 54.19%
Depreciation, Depletion And Amortization $180.0K $170.0K
YoY Change 5.88% 21.43%
Cash From Operating Activities -$15.01M -$7.220M
YoY Change 107.89% 123.53%
INVESTING ACTIVITIES
Capital Expenditures -$3.180M -$4.440M
YoY Change -28.38% 737.74%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.180M -$4.440M
YoY Change -28.38% 737.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 160.0K 30.00K
YoY Change 433.33% -99.48%
NET CHANGE
Cash From Operating Activities -15.01M -7.220M
Cash From Investing Activities -3.180M -4.440M
Cash From Financing Activities 160.0K 30.00K
Net Change In Cash -18.03M -11.63M
YoY Change 55.03% -687.37%
FREE CASH FLOW
Cash From Operating Activities -$15.01M -$7.220M
Capital Expenditures -$3.180M -$4.440M
Free Cash Flow -$11.83M -$2.780M
YoY Change 325.54% 2.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4465000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4825000
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2176000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1466000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-166000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-201000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1126000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
886000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4040000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3355000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5221974
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4998343
CY2016Q3 us-gaap Assets
Assets
78292000
CY2015Q4 us-gaap Assets
Assets
109358000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
48841000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
93041000
CY2016Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
0
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
446000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
178000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46793000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91051000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57329000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105680000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-44258000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
48351000
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15
CY2016Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2015Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32443792
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32279106
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
238808000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
233902000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12460000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10813000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36327000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25452000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk </div></div><div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div></div></div></div>
us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
1267000
us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
1034000
CY2016Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
19369000
CY2015Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
10371000
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
22000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17000
us-gaap Depreciation
Depreciation
525000
us-gaap Depreciation
Depreciation
510000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
36000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
142000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2015Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-25000
CY2015Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
78000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-41000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-155000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2685000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1083000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7521000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4542000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2074000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1124000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
710000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-524000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
6000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
12000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
58000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1496000
CY2016Q3 us-gaap Liabilities
Liabilities
6663000
CY2015Q4 us-gaap Liabilities
Liabilities
6308000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78292000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109358000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6641000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6291000
CY2016Q3 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
0
CY2015Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
866000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77468000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11946000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6646000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33214000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22613000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-12484000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-10736000
us-gaap Net Income Loss
NetIncomeLoss
-36363000
us-gaap Net Income Loss
NetIncomeLoss
-25594000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
78000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-155000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
12459000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
10814000
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
24000
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-77000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
900000
CY2015Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2400000
us-gaap Operating Expenses
OperatingExpenses
36322000
us-gaap Operating Expenses
OperatingExpenses
25439000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
12459000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
10814000
us-gaap Operating Income Loss
OperatingIncomeLoss
36322000
us-gaap Operating Income Loss
OperatingIncomeLoss
25439000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
36000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
142000
us-gaap Payments For Construction In Process
PaymentsForConstructionInProcess
7731000
us-gaap Payments For Construction In Process
PaymentsForConstructionInProcess
4687000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-325000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4215000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1959000
CY2016Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2015Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2048000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1990000
CY2015Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
70600000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
866000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
678000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
76055000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000
CY2015Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
700000
CY2015Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
CY2015Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
600000
us-gaap Share Based Compensation
ShareBasedCompensation
4040000
CY2015Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3100000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10082000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5946000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9774000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9731000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28801000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20897000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167013000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-130651000
us-gaap Share Based Compensation
ShareBasedCompensation
3355000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.66
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
48250
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
63375
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
286625
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
357833
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
398500
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
242000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.50
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.99
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4786577
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5083160
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5281715
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5221974
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.56
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.48
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.92
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.55
CY2015Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.50
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.50
CY2016Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.96
CY2016Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.51
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.50
CY2016Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.87
CY2016Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.98
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.01
CY2016Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.43
CY2016Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.73
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
208333
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
164686
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15000
CY2015Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
106000
CY2015Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12000
CY2015Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
226141
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
13000
CY2016Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
136570
CY2016Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15116
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
71629000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
103050000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Use of Estimates </div></div><div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0">The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</div><div style=" font-size: 10pt; margin: 0pt 0">Prior to the completion of its initial public offering in April 2015, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The board of directors determined the estimated fair value of the Company&#x2019;s common stock based on a number of objective and subjective factors, including the prices at which the Company sold shares of its common stock to third parties and external market conditions affecting the biotechnology industry sector. After the initial public offering, the fair market value is calculated by using the closing price of the Company&#x2019;s common stock as reported by NASDAQ.</div></div></div></div>
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32436207
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32050565
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32367588
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30342741
CY2015Q1 xbit Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
164999
xbit Proceeds From Collection Of Subscription Receivable
ProceedsFromCollectionOfSubscriptionReceivable
xbit Proceeds From Collection Of Subscription Receivable
ProceedsFromCollectionOfSubscriptionReceivable
410000
CY2016Q3 xbit Projected Additional Capital Expenditures
ProjectedAdditionalCapitalExpenditures
5600000
CY2016Q3 xbit Projected Additional Construction In Progress Expenditures
ProjectedAdditionalConstructionInProgressExpenditures
1200000

Files In Submission

Name View Source Status
0001171843-16-013213-index-headers.html Edgar Link pending
0001171843-16-013213-index.html Edgar Link pending
0001171843-16-013213.txt Edgar Link pending
0001171843-16-013213-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_111416p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbit-20160930.xml Edgar Link completed
xbit-20160930.xsd Edgar Link pending
xbit-20160930_cal.xml Edgar Link unprocessable
xbit-20160930_def.xml Edgar Link unprocessable
xbit-20160930_lab.xml Edgar Link unprocessable
xbit-20160930_pre.xml Edgar Link unprocessable